title: Effects of coenzyme Q10 on the heart ultrastructure and nitric oxide synthase during hyperthyroidism.
abstract: Coenzyme Q10 is an important component of mitochondrial electron transport chain and antioxidant. Hyperthyroidism manifests hyperdynamic circulation with increased cardiac output, increased heart rate and decreased peripheral resistance. The heart is also under the oxidative stress in the hyperthyroidism. The aim of this study was to examine both how the coenzyme Q10 can affect heart ultrastructure in the hyperthyroidism and how the relationship between nitric oxide synthase (NOS) and heart damage and coenzyme Q10. Swiss Black C57 mice received 5 mg/kg L-thyroxine. Coenzyme Q10 (1.5 mg/kg) and L-thyroxine together was given to second group mice. Coenzyme Q10 and serum physiologic were applied to another two groups, respectively. All treatments were performed daily for 15 days by gavage. Free triiodothyronine and thyroxine were increased in two groups given L-thyroxine; thyroid-stimulating hormone level did not change. Hyperthyroid heart showed an increased endothelial NOS (eNOS) and inducible NOS (iNOS) immunoreactivity in the tissue. Coenzyme Q10 administration decreased these NOS immunoreactivities in the hyperthyroid animals. Cardiomyocytes of the hyperthyroid animals was characterized by abnormal shape and invaginated nuclei, and degenerative giant mitochondria. Desmosome plaques reduced in density. In hyperthyroid mice given coenzyme Q10, the structural disorganization and mitochondrial damage regressed. However, hearts of healthy mice given coenzyme Q10 displayed normal ultrastructure, except for increased mitochondria and some of them were partially damaged. Coenzyme Q10 increased the glycogen in the cardiomyocytes. In conclusion, coenzyme Q10 administration can prevent the ultrastructural disorganization and decrease the iNOS and eNOS increment in the hyperthyroid heart.
authors.affiliation: Department of Biology, Faculty of Science, Istanbul University, Vezneciler. fusunoztay@yahoo.com
authors.forename: Fusun
authors.initials: F
authors.lastname: Oztay
authors.forename: Bulent
authors.initials: B
authors.lastname: Ergin
authors.forename: Savas
authors.initials: S
authors.lastname: Ustunova
authors.forename: Huriye
authors.initials: H
authors.lastname: Balci
authors.forename: Aysegul
authors.initials: A
authors.lastname: Kapucu
authors.forename: Metin
authors.initials: M
authors.lastname: Caner
authors.forename: Cihan
authors.initials: C
authors.lastname: Demirci
mesh_terms: D000818:Animals; D006321:Heart / Q000187:drug effects*; D006980:Hyperthyroidism / Q000201:enzymology*; D007150:Immunohistochemistry; D008297:Male; D051379:Mice; D008854:Microscopy, Electron; D009206:Myocardium / Q000201:enzymology* / Q000648:ultrastructure*; D052247:Nitric Oxide Synthase Type II / Q000378:metabolism*; D052250:Nitric Oxide Synthase Type III / Q000378:metabolism*; D014451:Ubiquinone / Q000031:analogs & derivatives* / Q000494:pharmacology
chemical_list: D014451:Ubiquinone; D052247:Nitric Oxide Synthase Type II; D052250:Nitric Oxide Synthase Type III; C024989:coenzyme Q10